Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | TACR2 | P21452 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SHBG | P04278 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | TST | Q16762 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358879 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL359592 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL176980 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL11031408 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL4297552 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL359570 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9600021 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL359311 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL7769065 | 0.98 | ESR1 (0.69) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL10985836 | 0.94 | RARB (0.62) | ESR1ADRA2AADORA3TACR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56138135-A | — | — | None | — | — | JP | disclosed |
| EP-3569608-B1 | OLIGOSACCHARIDE COMPOUND FOR INHIBITING ENDOGENOUS COAGULATION FACTOR X-ENZYME COMPLEX, AND PREPARATION METHOD THEREFOR AND USES THEREOF | JIUZHITANG CO LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12280072-B2 | Oligosaccharide compound for inhibiting intrinsic coagulation factor X-enzyme complex, and preparation method therefor and uses thereof | JIUZHITANG CO., LTD. (CN) | 2025-04-22 | — | — | US | disclosed |
| CN-119219629-A | N-benzyl imidazopyridine derivative and preparation method and application thereof | 中国药科大学 | 2024-12-31 | — | — | CN | disclosed |
| US-20240041918-A1 | Oligosaccharide Compound for Inhibiting Intrinsic Coagulation Factor X-Enzyme Complex, and Preparation Method Therefor and Uses Thereof | JIUZHITANG CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| US-11840601-B2 | Composition of alkoxysilyl-functionalized epoxy resin and composite thereof | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11833169-B2 | — | — | 2023-12-05 | — | — | US | disclosed |
| CN-108285498-B | Oligosaccharide compound for inhibiting endogenous coagulation factor X enzyme complex and preparation method and application thereof | 九芝堂股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20200254003-A1 | OLIGOSACCHARIDE COMPOUND FOR INHIBITING INTRINSIC COAGULATION FACTOR X-ENZYME COMPLEX, AND PREPARATION METHOD THEREFOR AND USES THEREOF | MUDANJIANG YOUBO PHARMACEUTICAL CO., LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| EP-3569608-A1 | OLIGOSACCHARIDE COMPOUND FOR INHIBITING ENDOGENOUS COAGULATION FACTOR X-ENZYME COMPLEX, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Jiuzhitang Co., Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-6090961-A | Method for producing titanium complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-07-18 | — | — | US | disclosed |
| EP-0992479-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0970964-A2 | Method for producing titanium complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5180521-A | Liquid crystal displays, cyclohexyl nitriles | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-01-19 | — | — | US | disclosed |
| EP-0224579-A1 | SMECTIC LIQUID CRYSTALLINE PHASES. | MERCK PATENT GMBH (DE) | 1987-06-10 | — | — | EP | disclosed |
| WO-1986007085-A1 | SMECTIC LIQUID CRYSTALLINE PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-12-04 | — | — | WO | disclosed |
| EP-0058512-B1 | LIQUID CRYSTAL COMPOUNDS EXHIBITING A SMALL DIELECTRIC ANISOTROPY AND LIQUID CRYSTAL MATERIALS AND DEVICES INCORPORATING SUCH COMPOUNDS | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1986-01-15 | — | — | EP | disclosed |
| US-4556745-A | BICYCOL(2.2.2) OCATANE RING | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1985-12-03 | — | — | US | disclosed |
| EP-0058512-A1 | Liquid crystal compounds exhibiting a small dielectric anisotropy and liquid crystal materials and devices incorporating such compounds | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1982-08-25 | — | — | EP | disclosed |
| JP-S56138135-A | LIQUID CRYSTAL COMPOUND | HITACHI LTD | 1981-10-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280072-B2 | Oligosaccharide compound for inhibiting intrinsic coagulation factor X-enzyme complex, and preparation method therefor and uses thereof | F11, F8, HABP2 | ESR1 4581/4885ADRA2A 4837/4885ADORA3 4561/4885 |
| US-20200254003-A1 | OLIGOSACCHARIDE COMPOUND FOR INHIBITING INTRINSIC COAGULATION FACTOR X-ENZYME COMPLEX, AND PREPARATION METHOD THEREFOR AND USES THEREOF | F11, F8, HABP2 | ESR1 4581/4885ADRA2A 4837/4885ADORA3 4561/4885 |
| US-20240041918-A1 | Oligosaccharide Compound for Inhibiting Intrinsic Coagulation Factor X-Enzyme Complex, and Preparation Method Therefor and Uses Thereof | F11, F8, HABP2 | ESR1 4581/4885ADRA2A 4837/4885ADORA3 4561/4885 |
| US-11833169-B2 | — | SERPINC1, HPSE, HABP2 | ESR1 4840/4885ADRA2A 4514/4885ADORA3 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.